TC BioPharm Holdings Performance
| TCBPDelisted Stock | USD 0.50 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and TC BioPharm are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days TC BioPharm Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, TC BioPharm is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 4.8 M | |
| Free Cash Flow | -10.7 M |
TCBP |
TC BioPharm Relative Risk vs. Return Landscape
If you would invest 50.00 in TC BioPharm Holdings on October 18, 2025 and sell it today you would earn a total of 0.00 from holding TC BioPharm Holdings or generate 0.0% return on investment over 90 days. TC BioPharm Holdings is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than TCBP, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TC BioPharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TC BioPharm's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as TC BioPharm Holdings, and traders can use it to determine the average amount a TC BioPharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TCBP |
Based on monthly moving average TC BioPharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TC BioPharm by adding TC BioPharm to a well-diversified portfolio.
TC BioPharm Fundamentals Growth
TCBP Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of TC BioPharm, and TC BioPharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TCBP Pink Sheet performance.
| Return On Equity | -5.77 | |||
| Return On Asset | -0.98 | |||
| Current Valuation | 1.01 M | |||
| Shares Outstanding | 512.99 K | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 0.51 X | |||
| EBITDA | (13.61 M) | |||
| Cash And Equivalents | 1.57 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 1.8 M | |||
| Book Value Per Share | 81.06 X | |||
| Cash Flow From Operations | (10.54 M) | |||
| Earnings Per Share | (4,794) X | |||
| Total Asset | 8.93 M | |||
| Retained Earnings | (38.84 M) | |||
About TC BioPharm Performance
Assessing TC BioPharm's fundamental ratios provides investors with valuable insights into TC BioPharm's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the TC BioPharm is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.Things to note about TC BioPharm Holdings performance evaluation
Checking the ongoing alerts about TC BioPharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for TC BioPharm Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TC BioPharm Holdings is not yet fully synchronised with the market data | |
| TC BioPharm Holdings has some characteristics of a very speculative penny stock | |
| TC BioPharm Holdings has a very high chance of going through financial distress in the upcoming years | |
| TC BioPharm Holdings currently holds 1.8 M in liabilities. TC BioPharm Holdings has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TC BioPharm until it has trouble settling it off, either with new capital or with free cash flow. So, TC BioPharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TC BioPharm Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TCBP to invest in growth at high rates of return. When we think about TC BioPharm's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
| TC BioPharm Holdings currently holds about 1.57 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from globenewswire.com: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People Culture |
- Analyzing TC BioPharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TC BioPharm's stock is overvalued or undervalued compared to its peers.
- Examining TC BioPharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TC BioPharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of TC BioPharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TC BioPharm's pink sheet. These opinions can provide insight into TC BioPharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in TCBP Pink Sheet
If you are still planning to invest in TC BioPharm Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TC BioPharm's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |